PHARMACOKINETICS/PHARMACODYNAMICS OF ANTICANCER DRUGS IN CHILDHOOD SOLID TUMORS

抗癌药物在儿童实体瘤中的药代动力学/药效学

• 批准号: 6101969
• 负责人: WILLIAM R CROM
• 金额: $ 16.71万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2000-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6101969
• 关键词: Macaca mulatta; antineoplastics; camptothecin; cerebrospinal fluid; clinical research; cytotoxicity; disease /disorder model; dosage; drug administration rate /duration; extracellular matrix; human tissue; laboratory mouse; medulloblastoma; microdialysis; model design /development; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; neuroblastoma; pediatric neoplasm /cancer; pharmacokinetics; rhabdomyosarcoma

Treatment failure in children with malignant solid tumors may be directly related to variability in anticancer drug disposition. However, children with cancer usually receive identical drug dosages, based on body size, without accounting for pharmacokinetic variability. Clinical pharmacokinetic-pharmacodynamic investigations in children are ofter descriptive, while animal models provide greater flexibility in designing preclinical hypothesis-testing studies. This project focuses on the application of pharmacokinetic/dynamic methodologies to characterize concentration-effect relationships of anticancer drugs in animal model systems, and to develop rational drug therapy regimens for the treatment of children with solid tumors, with particular emphasis on camptothecin analogs. The specific aims of this project are: 1) to establish parmacokinetic-pharmacodynamic relationships of camptothecin anticancer drugs in human tumor xenograft models; 2) to determine the concentration profile of camptothecins in the extracellular fluid (ECF) of xenografts; 3) to elucidate the underlying mechanisms responsible for altered drug disposition in tumor-bearing mice compared to nontumor-bearing mice; 4) to develop a pharmacokinetic model to predict disposition of camptothecins in the CSF; and 5) to identify the optimal schedules and pharmacokinetic exposures producing antitumor activity for other new agents. These aims will be addressed primarily with the murine pediatric tumor xenograft model and in nonhuman primates to characterize cerebrospinal fluid disposition of drugs. Models of drug distribution into extracellular fluid (ECF) will be developed and validated using microdialysis methods. Within this program, the concentrations, exposure times, and intervals between exposures that optimize cytotoxicity will be characterized in vitro. In this project, these studies will be extended in vivo, using unique xenograft models of childhood solid tumors, to evaluate systemic exposure, tissue exposure, and tumor responses, and to construct pharmacodynamic models for clinical use. Studies of ECF and plasma drug concentrations will determine whether rates or duration of drug administration alter distribution into tumor tissues. Laboratory studies will be undertaken to identify altered drug metabolism pathways in mice bearing xenographs, compared to normal mice. Translation of the findings from this project will be incorporated into clinical studies to develop optimal dosing regimens and to verify the relatonships identified in the animal models.

恶性实体瘤儿童的治疗失败可能是 与抗癌药物处置的可变性直接相关。 但是，患有癌症的儿童通常会接受相同的药物剂量， 基于身体大小，而无需考虑药代动力学变异性。 儿童的临床药代动力学 - 药物动力学研究 具有描述性，而动物模型提供了更大的灵活性 在设计临床前假设检验研究中。 这个项目 专注于将药代动力学/动态方法应用于 表征抗癌药物的浓度效应关系 动物模型系统，并开发合理的药物治疗方案 对实体瘤儿童的治疗，特别是 在camptothecin类似物上。 该项目的具体目的是：1） 建立camptothecin 人类肿瘤异种移植模型中的抗癌药； 2）确定 凸甲虫在细胞外流体（ECF）中的浓度剖面 异种移植物； 3）阐明负责的基本机制 相比 非肿瘤的小鼠； 4）开发药代动力学模型以预测 在CSF中倾斜甲虫； 5）确定最佳 时间表和药代动力学暴露产生抗肿瘤活性 对于其他新代理商。 这些目标将主要通过 鼠儿科肿瘤异种移植模型和非人类灵长类动物 表征药物的脑脊液处置。 药物模型 将开发到细胞外液体（ECF）中，并将开发 使用微透析方法验证。 在此程序中， 浓度，暴露时间和暴露之间的间隔 优化细胞毒性将在体外表征。 在这个项目中， 这些研究将使用独特的异种移植模型在体内扩展 儿童实体瘤，以评估全身暴露，组织 暴露和肿瘤反应，并构建药效学模型 用于临床用途。 对ECF和血浆药物浓度的研究将 确定药物施工的比率或持续时间是否改变 分布到肿瘤组织中。 将进行实验室研究 确定轴承小鼠的药物代谢途径改变 与正常小鼠相比，Xenographs。 调查结果的翻译 该项目将被纳入临床研究以开发 最佳给药方案并验证在 动物模型。